J Nanobiotechnology April 2023 PMID 37005668

Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.

Hao Zhang, Wang Zhang, Bochuan Hu, Xiaohua Qin, Tianxiang Yi, Yayi Ye, Xiaowan Huang, Yang Song, Zhenyu Yang, Jieying Qian, Yunjiao Zhang

Full text PDF Download social card

Mentions

Peak: 2 in Apr 2023

across 2 sources since Apr 2023

Extended reach

1,135

potential audience

Total likes

Video views

170

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions emphasize the innovative use of cerium oxide nanoparticles to target mutant p53 in pancreatic cancer, with words like "promising," "exciting," and "breakthrough" conveying optimism. The tone is generally positive yet somewhat cautious, acknowledging the potential impact while recognizing that these findings are preliminary.

AgreementModerate agreement

Most discussions express support or fascination with the potential of the research, indicating general agreement on its significance.

InterestModerate interest

Participants show moderate curiosity, often emphasizing the innovative approach and potential benefits without deep technical engagement.

EngagementModerate engagement

Comments often highlight the promising nature of the findings but lack detailed analysis, suggesting a moderate level of involvement.

ImpactModerate impact

The discussions reflect optimism about the therapy's future influence, though it's mostly speculative without concrete clinical results yet.

Abstract in brief

The study explores a targeted treatment for pancreatic cancer by using cerium oxide nanoparticles (CeO NPs) to induce the degradation of mutant p53 proteins, which are common in many cancers and promote tumor growth.
CeO NPs increase reactive oxygen species (ROS) specifically in cancer cells, leading to the ubiquitination and breakdown of mutp53 proteins, without harming healthy cells, thereby reducing tumor cell proliferation and migration.
This approach restores some normal cell functions and significantly improves therapeutic outcomes in a pancreatic cancer model, making CeO NPs a promising targeted cancer treatment strategy.]

Read the full abstract

All mentions

Targeted Degradation of Mutant p53 for Pancreatic Cancer Therapy

This study investigates using cerium oxide nanoparticles to induce ubiquitination and degradation of mutant p53 proteins in pancreatic cancer cells, reducing tumor growth without harming healthy cells, offering a…

STEM RTCL TV · Jul 23, 2023 170 views

DNA-binding drugs

@DNAbinding · X

Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles https://t.co/CzNE6yDyPx

Apr 4, 2023 · 1 like · 670 followers View post →

Hammed Onilude (PhD)

@HammedOnilude · X

Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles https://t.co/as06xJ5gYO

Apr 2, 2023 · 296 followers View post →